ストックスクリーナーアプリを入手
6.73
3.72%
-0.26
プレマーケット:
6.90
0.17
+2.53%
前日終値:
$6.99
開ける：
$6.76
24時間の取引高:
6.31M
Relative Volume:
6.17
時価総額：
$633.00M
収益：
-
当期純損益:
$-106.81M
株価収益率:
-2.0322
EPS:
-3.3117
ネットキャッシュフロー:
$-8.40M
1週間 パフォーマンス:
-17.42%
1か月 パフォーマンス:
-28.40%
6か月 パフォーマンス:
-53.97%
1年 パフォーマンス:
-72.73%
1日の値動き範囲:
$6.41
$6.855
1週間の範囲:
$6.41
$8.24
52週間の値動き範囲:
$6.41
$24.86
Immunome Inc Stock (IMNM) Company Profile
IMNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
6.73 | 633.00M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-04-30 | 開始されました | JP Morgan | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-01-29 | 開始されました | Leerink Partners | Outperform |
| 2023-12-19 | 開始されました | Wedbush | Outperform |
| 2021-10-29 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Immunome Inc (IMNM) 最新ニュース
Immunome stock hits 52-week low at $6.94 amid market challenges By Investing.com - Investing.com South Africa
Immunome stock hits 52-week low at $6.94 amid market challenges - Investing.com India
Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity - Defense World
Immunome (IMNM) Stock Climbs as Executives Increase Holdings - GuruFocus
Immunome director Jean Jacques Bienaime acquires $60,684 in stock - Investing.com
Immunome CEO Clay Siegall buys $999k in stock By Investing.com - Investing.com Canada
Immunome director Jean Jacques Bienaime acquires $60,684 in stock By Investing.com - Investing.com UK
Immunome CEO Clay Siegall buys $999k in stock - Investing.com India
Immunome stock rises after insider purchase (IMNM:NASDAQ) - Seeking Alpha
Immunome director Jean Jacques Bienaime purchases $57,470 in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome CTO Philip Tsai purchases $103,566 in stock By Investing.com - Investing.com Canada
Immunome director Jean Jacques Bienaime purchases $57,470 in stock - Investing.com
Immunome CTO Philip Tsai purchases $103,566 in stock - Investing.com
Bank of New York Mellon Corp Has $1.31 Million Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wedbush Has Positive Estimate for Immunome Q1 Earnings - Defense World
Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush - Defense World
Guggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock Price - Defense World
Stephens Reiterates Overweight Rating for Immunome (NASDAQ:IMNM) - Defense World
Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com
Immunome Full Year 2024 Earnings: Misses Expectations - Yahoo
Immunome’s 2024 Financial Results and Pipeline Progress - TipRanks
Immunome stock target cut to $25 by Guggenheim - Investing.com Australia
Immunome (IMNM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Immunome earnings missed by $0.45, revenue fell short of estimates - Investing.com Canada
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Immunome 2024 Net Loss Narrows -March 19, 2025 at 05:07 pm EDT - Marketscreener.com
Immunome Inc. (IMNM) reports earnings - Quartz
Immunome Inc. SEC 10-K Report - TradingView
Immunome Reports Full Year 2024 Financial Results and Provides Business Update - The Bakersfield Californian
Immunome stock hits 52-week low at $8.37 amid market challenges - Investing.com Australia
Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan
Immunome stock hits 52-week low at $8.37 amid market challenges By Investing.com - Investing.com South Africa
With 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional owners - Yahoo
Immunome, Inc. (NASDAQ:IMNM) Receives $27.17 Average PT from Analysts - MarketBeat
Lifesci Capital Predicts Immunome FY2024 Earnings - Defense World
Q1 Earnings Forecast for Immunome Issued By Lifesci Capital - Defense World
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $27.17 - Defense World
Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation - Nasdaq
Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Immunome stock hits 52-week low at $8.53 amid market challenges - Investing.com Australia
Immunome stock hits 52-week low at $8.53 amid market challenges By Investing.com - Investing.com South Africa
Immunome doses first patient in early-stage trial of its experimental cancer treatment -March 10, 2025 at 08:23 am EDT - Marketscreener.com
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Joplin Globe
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 - BioSpace
Immunome (NASDAQ:IMNM) Sets New 52-Week LowHere's Why - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Immunome Inc (IMNM) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):